All News

Posters presented at the 2023 Fall Clinical Dermatology Conference evaluated how label warnings may affect new treatment initiation and real-word switching patterns for patients starting risankizumab.

Understanding the needs of gender-diverse patients and patients receiving gender-affirming hormones is crucial to equitable care and properly addressing patients' needs.

This retrospective review compared appendicular lean mass (ALM) and ALM index among patients with Duchenne muscular dystrophy (DMD) or Becker muscular dystrophy (BMD).

Given the likelihood of MDS to progress to acute myeloid leukemia (AML), the authors state, “There are certain settings where ‘AML-like’ therapies are appropriate in MDS, particularly given our evolving understanding of the overlapping biology of these malignancies.”

HADLIMA is currently indicated for psoriatic arthritis, plaque psoriasis, and hidradenitis suppurativa, among others.

A study suggests that human papillomavirus (HPV) screenings should be updated due to effective HPV vaccines; a new study shows that osimertinib (Tagrisso, AstraZeneca) reduced both the 5-year risk of recurrent cancer and the risk of death in patients with stage 1B to 3A lung cancer; a new smartphone-controlled technology could help those who suffer from migraines.

The FDA has approved fruquintinib (Fruzaqla) for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.

Industry stakeholders and patient advocacy groups are raising concerns with CMS due to high denial rates for non-invasive ventilators (NIVs) by Medicare Advantage plans.

Investigators propose potential payment models for gene therapies that consider equitable patient access and payer reimbursement.

A retrospective analysis suggested that administering rituximab to patients with rheumatoid arthritis complicated by lymphoma, systemic vasculitis, or extra-articular lesions was associated with improved outcomes.

Tirzepatide is already approved to treat type 2 diabetes, and is now approved for chronic weight management in adults with obesity or overweight with at least 1 weight-related condition.

Smoking intensity was shown to be associated with larger microvasculature dropout areas in patients with glaucoma, particularly those with more severe disease.

Three new novel treatments have shown promise in the treatment of multiple sclerosis (MS), including the potential to target neuroinflammation at its source.

Medicare may cover full cost of preexposure prophylaxis drugs; rules aim to prevent excessive compensation in Medicare Advantage (MA) market; health officials advocate for widespread syphilis testing and intervention.

When patients are undergoing treatment for cancer, clinicians should be aware of the potential to develop myasthenia gravis from immune checkpoint inhibitors (ICI), new research stresses, with ongoing surveillance and risk factor identification becoming necessary steps.

High levels of phenotypic age acceleration (PhenoAgeAccel) were found to have a more significant effect on lung function in patients with chronic obstructive pulmonary disease (COPD), older patients, and White patients.

Researchers provide progression-free survival outcomes for a pancreatic cancer vaccine and safety and efficacy results for a peptide vaccine alone or in combination with pembrolizumab.

Caecal cancer and ascending colon cancer had slower rates of metastasis to main nodes compared with transverse colon cancer.

Artificial intelligence (AI) could help detect heart attack risk signs and prevent sudden cardiac death; Advocates demand the Biden administration finalize the proposed FDA ban on menthol cigarettes; Gun violence survivors and their families have many ongoing medical needs.

Acute kidney injury (AKI) was found to be common in children aged 17 years and younger who were hospitalized for sickle cell anemia.

Despite the growing availability of prescription digital therapeutics (PDTs) coming to market, few products have gone through rigorous standards of evidence testing, according to one study.

Rhenium (186Re) obisbemeda (Plus Therapeutics) shows potential to address the unmet need of new treatment options for patients with breast cancer and leptomeningeal metastases and will continue to be evaluated in the ReSPECT-LM program. The orphan drug designation (ODD) was granted on November 3.

Intravitreal aflibercept was used in patients with retinal vein occlusion (RVO) which led to functional and anatomic improvements in the patients after treatment.

Phathom Pharmaceuticals' vonoprazan (Voquenza) sets a new standard in erosive gastroesophageal reflux disease (GERD) therapy.

CDC plans to monitor over 30 pathogens in high-risk airports; a surge in ketamine prescriptions raises questions about safety and oversight; changes to come in Affordable Care Act (ACA) enrollment for 2023.

The prevalence of severely elevated low-density lipoprotein cholesterol (LDL-C) has declined in recent decades, but 1 in 17 US adults in a recent analysis had levels of LDL-C that would warrant consideration of pharmacotherapy, and 1 in 48 had high levels of LDL-C that are indicated for medication.

The prevalence of eosinophilic asthma and severe asthma phenotypes was high in many countries, according to one study.

Patient input and experiences play a crucial role in advancing rare disease research and therapy development, as they help define the disease, inform clinical trial design, and influence regulators and payers' decisions, ultimately serving as catalysts for innovation in the field.